Top Industry Leaders in the Microbial Products Market
Latest Microbial Products Companies Update
Nov 2023: A definitive agreement was announced by Merck MRK to purchase Caraway Therapeutics, a private biotech company, in the pre-clinical stage for a possible considering up to $610 million. Caraway Therapeutics develops novel mechanisms of action to produce medications for uncommon and genetically determined neurodegenerative illnesses. An unknown upfront payment and contingent milestone payments dependent on the progress of a few pipeline candidates make up the purchase consideration. Merck has invested in Caraway Therapeutics through its MRL Ventures Fund since 2018. Caraway Therapeutics' board of directors has already accepted the agreement.
Amgen and US biotech PostEra have teamed up for a multi-target drug research partnership. To advance up to five small molecule programs, the firms will leverage Amgen's experience in drug discovery and PostEra's artificial intelligence (AI) platform, Proton. The Proton platform is a comprehensive machine-learning platform designed to eliminate medicinal chemistry's costly and time-consuming design-make-test cycle. From 2020 to 2022, PostEra and Pfizer had a continuous partnership extended in exchange for $13 million in up-front payments and $248 million in downstream milestones. In January 2022, the firm proclaimed the completion of a $24 million Series A fundraising transaction concurrent with the Pfizer expansion agreement.
List of Microbial Products Key companies in the market
- Amgen Inc.
- Merck & Co. Inc.
- VALENT Biosciences Corp.
- GlaxoSmithKline plc.
- Pfizer Inc.
- BIOMÉRIEUX SA
- Ajinomoto Co. Inc.
- SANOFI S.A
- Novartis AG
- NOVADIGM Therapeutics
- Kyowa Hakko Bio Co.